Research programme: second-generation Gadd45-beta protein gene inhibitors - Kesios Therapeutics
Latest Information Update: 28 Nov 2018
At a glance
- Originator Imperial College of Science, Technology and Medicine
- Developer Kesios Therapeutics
- Class
- Mechanism of Action GADD45B protein inhibitors; Gene expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Multiple myeloma
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 Nov 2018 No recent reports of development identified for research development in Multiple-myeloma in United Kingdom